{
    "Symbol": "BGNE",
    "AssetType": "Common Stock",
    "Name": "BeiGene Ltd",
    "Description": "BeiGene, Ltd. discovers, develops, manufactures and markets cancer therapeutics drugs in the People's Republic of China and the United States. The company is headquartered in Beijing, the People's Republic of China.",
    "CIK": "1651308",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, KY",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "18089978000",
    "EBITDA": "-1009803008",
    "PERatio": "None",
    "PEGRatio": "0",
    "BookValue": "32.13",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-7.55",
    "RevenuePerShareTTM": "26.46",
    "ProfitMargin": "-0.284",
    "OperatingMarginTTM": "-0.348",
    "ReturnOnAssetsTTM": "-0.118",
    "ReturnOnEquityTTM": "-0.209",
    "RevenueTTM": "2762630000",
    "GrossProfitTTM": "-511062000",
    "DilutedEPSTTM": "-7.55",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "0.679",
    "AnalystTargetPrice": "267.69",
    "AnalystRatingStrongBuy": "8",
    "AnalystRatingBuy": "13",
    "AnalystRatingHold": "2",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "-",
    "PriceToSalesRatioTTM": "6.34",
    "PriceToBookRatio": "4.174",
    "EVToRevenue": "5.43",
    "EVToEBITDA": "-11.91",
    "Beta": "0.591",
    "52WeekHigh": "219.64",
    "52WeekLow": "126.97",
    "50DayMovingAverage": "154.91",
    "200DayMovingAverage": "163.57",
    "SharesOutstanding": "97023000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}